SAN ANTONIO--(BUSINESS WIRE)--iTraumaCare, an early-stage medical device firm focused on developing traumatic injury solutions, has achieved its fourth regulatory milestone with an expanded indication for use from the US Food and Drug Administration (FDA). The regulatory body has expanded the indications for the company’s first product, the iTClampTM Hemorrhage Control System, to include the temporary control of severe bleeding of the scalp. Previously, the product’s indications for use in the US included only the extremities (arms and legs), axilla (arm pit) and inguinal (groin) areas.
Help employers find you! Check out all the jobs and post your resume.
